17 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
INCY: Oppenheimer ups to Outperform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20190905063824 Sep 05, 2019 - Oppenheimer issues rating change for INCY
INCY: BMO Capital Markets starts at Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20190911190500 Sep 11, 2019 - BMO Capital Markets issues rating change for INCY
INCY: BMO Capital Markets starts at Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20190913142141 Sep 13, 2019 - BMO Capital Markets issues rating change for INCY
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx http://www.zacks.com/stock/news/549301/puma-biotech-gets-fda-nod-of-labeling-supplement-for-nerlynx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-549301 Oct 04, 2019 - The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
Seattle Genetics Begins Phase III Study on Tucatinib Combo http://www.zacks.com/stock/news/559754/seattle-genetics-begins-phase-iii-study-on-tucatinib-combo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-559754 Oct 11, 2019 - Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
Editas Inks Deal for Gene Editing Neurological Disease Drugs http://www.zacks.com/stock/news/567847/editas-inks-deal-for-gene-editing-neurological-disease-drugs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-567847 Oct 16, 2019 - Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Novavax Begins Phase III Study on Influenza Vaccine Candidate http://www.zacks.com/stock/news/567846/novavax-begins-phase-iii-study-on-influenza-vaccine-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-567846 Oct 16, 2019 - Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD http://www.zacks.com/stock/news/569743/novartis-jakavi-meets-primary-goal-in-phase-iii-for-gvhd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569743 Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Why the Earnings Surprise Streak Could Continue for Incyte (INCY) http://www.zacks.com/stock/news/571171/why-the-earnings-surprise-streak-could-continue-for-incyte-incy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-571171 Oct 18, 2019 - Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings? http://www.zacks.com/stock/news/575739/whats-in-the-cards-for-astrazeneca-azn-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-575739 Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.

Pages: 12

Page 1